Merck’s Keytruda and Astellas/Pfizer’s Padcev recommended by CHMP for advanced bladder cancer
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) in combination with Astellas/Pfizer’s Padcev (enfortumab vedotin) has been recommended by the European Medicines Agency’s human medicines committee as a first-line …